Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Galectin Therapeutics Inc.

Contributing Author

Recent Articles by Galectin Therapeutics Inc.

Sep-10
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference GALT GlobeNewswire
Aug-14
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update GALT GlobeNewswire
Aug-04
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet GALT GlobeNewswire
Jun-23
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension GALT +11.43% GlobeNewswire
May-27
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis GALT GlobeNewswire
May-15
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update GALT -7.66% GlobeNewswire
May-11
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology GALT +5.24% GlobeNewswire
Mar-31
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update GALT +8.56% GlobeNewswire
Mar-17
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. GALT GlobeNewswire
Feb-26
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET GALT GALT -5.10% GlobeNewswire
Dec-19
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 GALT -28.90% GlobeNewswire
Nov-14
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GALT GlobeNewswire
Nov-10
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GALT GlobeNewswire
Oct-20
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GALT GlobeNewswire
Oct-07
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GALT +7.43% GlobeNewswire
Sep-02
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GALT GlobeNewswire
Aug-14
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GALT GlobeNewswire
Jul-09
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GALT +7.66% GlobeNewswire
Jun-10
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension GALT GlobeNewswire
May-15
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update GALT GlobeNewswire
May-12
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress GALT GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)